Who
John C. Reed
Director
Company insider
Files Form 4 as: Director, Madrigal Pharmaceuticals; EVP, Innovative Medicine, R&D, Johnson & Johnson; Director, Ionis Pharmaceuticals; Director, Clovis Oncology; Director, Repros Therapeutics; Director, Pharmion; Director, Stratagene.
In numbers
- Trades disclosed
- 97
- Buys
- 2
- Sells
- 7
- Bought
- $187K
- Sold
- $33.9M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 1 Jun 2006
- Last trade
- 15 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Aug 2026filed 18 Aug 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —647 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,078 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,078 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —647 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | —25,255 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code F | $2.5M11,002 at $229.85 | filing |
| 1 May 2026filed 4 May 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,255 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,255 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | —25,255 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code F | $2.5M11,002 at $229.85 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —21,721 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —29,927 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —21,721 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —29,927 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $3.4M21,721 at $157.92 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $5.3M21,721 at $243.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $4.7M29,927 at $156.15 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $7.3M29,927 at $243.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $3.4M21,721 at $157.92 | filing |
| 17 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $5.3M21,721 at $243.00 | filing |
News
Johnson & Johnson Introduce Coronary IVL CatheterJNJ · dicardiology.com · 20 Oct 2026Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?JNJ · insidermonkey.com · 20 Oct 2026Johnson & Johnson's Dividend Machine Is Running. Can Earnings Keep Up?JNJ · insidermonkey.com · 19 Oct 2026
0 headlines in the last 90 days name John C. Reed; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.